NASDAQ$GEHC
GE HealthCare Technologies Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
GE HealthCare reported its financial results for the second quarter of 2023, showing revenue growth and progress on operating priorities, leading to raised full-year guidance.
GE HealthCare's Q2 2023 results showed a 7% increase in revenue, with organic revenue growth of 9%. Net income was $418 million, and adjusted EBIT was $711 million. The company raised its full-year guidance for organic revenue growth and adjusted EPS.
- Revenue increased by 7% year-over-year, with 9% organic revenue growth.
- Organic orders grew by 6%, reflecting strong global demand.
- Net income attributable to GE HealthCare was $418 million.
- The company raised full-year guidance for organic revenue growth and adjusted EPS.
Headline financials
Revenue & EPS history
GE HealthCare · Revenue · Quarterly
$4.82B
Revenue by segment
GE HealthCare · $3.98B total across 4 segments · Q2 2023
- Imaging$2.62B+7.0%65.9%
- Patient Care$770M+8.0%19.4%
- Pharma Diagnostics$568M+18.8%14.3%
- Other$20M+25.0%0.5%
Forward guidance
The Company updated its guidance for full year 2023 with organic revenue growth in the range of 6% to 8% year-over-year and Adjusted EPS in the range of $3.70 to $3.85.
Tailwinds
- Organic revenue growth in the range of 6% to 8% year-over-year.
- Adjusted EBIT margin in the range of 15.0% to 15.5%.
- Adjusted effective tax rate (ETR) in the range of 23% to 25%.
- Adjusted EPS in the range of $3.70 to $3.85.
- Free cash flow conversion of 85% or more for the full year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q2 2023
-0.2%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.3%
Avg return
30 days after
50%
8 / 16 earnings
Positive
+11.5%
Q4 2021
Best reaction
-12.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.9% | -10.9% | -8.9% | |
| Q4 2025 | +6.4% | +0.4% | -5.7% | |
| Q3 2025 | -2.7% | -6.2% | +0.7% | |
| Q1 2025 | +3.3% | +1.9% | +3.6% | |
| Q4 2024 | +8.8% | +7.9% | -4.6% | |
| Q3 2024 | +2.4% | +2.0% | -2.4% | |
| Q2 2024 | +0.9% | -1.4% | +2.6% | |
| Q1 2024 | -12.0% | -10.6% | -11.7% | |
| Q4 2021 | +11.5% | +10.8% | +26.2% | |
| Q3 2023 | +8.1% | +13.3% | +8.4% | |
| Q3 2022 | +8.1% | +13.3% | +8.4% | |
| Q2 2023 | -4.0% | -3.4% | -15.1% | |
| Q1 2023 | -8.7% | -7.3% | -9.0% | |
| Q1 2022 | -8.7% | -7.3% | -9.0% | |
| Q2 2022 | -2.3% | +0.8% | +4.4% | |
| Q4 2022 | -0.8% | +0.7% | +7.4% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro